Ocugen (OCGN) Amortization of Deferred Charges (2014 - 2026)
Ocugen posted quarterly Amortization of Deferred Charges of $377000.0 for Q1 2026, up 25.67% year-on-year from $300000.0 in Q1 2025, and up 25.67% on a QoQ basis from $300000.0 in Q1 2025.
Ocugen (OCGN) has 3 years of Amortization of Deferred Charges data on file, last reported at $377000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 25.67% year-over-year to $377000.0; the trailing twelve-month figure through Mar 2026 stood at $833000.0 (up 121.54% YoY), and the FY2025 full-year result was $1.4 million, up 8412.5% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $377000.0, up from $300000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $377000.0 in Q1 2026 and bottomed at $300000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 377,000.00 |
| Mar 31, 2026 | 377,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2014 | 77,000.00 |
| Dec 31, 2014 | 77,000.00 |
| Sep 30, 2014 | 79,000.00 |
| Sep 30, 2014 | 79,000.00 |
| Jun 30, 2014 | -80,000.00 |
| Jun 30, 2014 | -80,000.00 |
| Mar 31, 2014 | -38,000.00 |
| Mar 31, 2014 | -38,000.00 |